<DOC>
	<DOCNO>NCT00769418</DOCNO>
	<brief_summary>This study ass safety , tolerability , pharmacokinetics , pharmacodynamics once-daily multiple-dose administration odanacatib ( MK0822 ) .</brief_summary>
	<brief_title>Study Multiple Oral Doses Odanacatib ( MK0822 ) Healthy Adults ( 0822-002 )</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<criteria>Subject male age 18 45 female less equal 70 year age Females must past menopause Subject nonsmoker Subject willing avoid excessive alcohol consumption study willing avoid alcohol entirely 24 hour prior drug administration PK sample Subject willing refrain consume grapefruit grapefruit juice Subject history multiple/severe allergy drug food Subject donate blood within 4 week start study Subject history metabolic bone disease , urolithiasis , bisphosphonate treatment Subject infection condition lead immune problem , include HIV Subject regularly us illegal drug Subject consumes 3 alcoholic beverage per day Subject drink 4 caffeinated beverage per day Subject use prescription nonprescription medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>